Recombinant interleukin-2 and other types of treatment of advanced malignant melanoma.

2.50
Hdl Handle:
http://hdl.handle.net/10541/108024
Title:
Recombinant interleukin-2 and other types of treatment of advanced malignant melanoma.
Authors:
Thatcher, Nick
Abstract:
Interleukin-2 has demonstrated significant and consistent activity against melanoma even in patients who have been treated previously with other modalities. This paper reviews local treatment, systemic treatment with single-agent, combination, and high-dose chemotherapy, and new agents; biologic modifier therapy, including tumor vaccines and active specific immunization, and interferons; and recombinant interleukin-2, which has activity when used alone, with lymphokine-activated killer cells, chemotherapy, or biologic modifiers. Tumor response, predictors of response, and survival are also discussed.
Affiliation:
Department of Medical Oncology, Christie Hospital and Holt Radium Institute, Withington, Manchester, England.
Citation:
Recombinant interleukin-2 and other types of treatment of advanced malignant melanoma. 1991, 3 (2):364-76 Curr Opin Oncol
Journal:
Current Opinion in Oncology
Issue Date:
Apr-1991
URI:
http://hdl.handle.net/10541/108024
PubMed ID:
2069998
Type:
Article
Language:
en
ISSN:
1040-8746
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorThatcher, Nicken
dc.date.accessioned2010-07-21T08:38:42Z-
dc.date.available2010-07-21T08:38:42Z-
dc.date.issued1991-04-
dc.identifier.citationRecombinant interleukin-2 and other types of treatment of advanced malignant melanoma. 1991, 3 (2):364-76 Curr Opin Oncolen
dc.identifier.issn1040-8746-
dc.identifier.pmid2069998-
dc.identifier.urihttp://hdl.handle.net/10541/108024-
dc.description.abstractInterleukin-2 has demonstrated significant and consistent activity against melanoma even in patients who have been treated previously with other modalities. This paper reviews local treatment, systemic treatment with single-agent, combination, and high-dose chemotherapy, and new agents; biologic modifier therapy, including tumor vaccines and active specific immunization, and interferons; and recombinant interleukin-2, which has activity when used alone, with lymphokine-activated killer cells, chemotherapy, or biologic modifiers. Tumor response, predictors of response, and survival are also discussed.en
dc.language.isoenen
dc.subject.meshAntineoplastic Agents-
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols-
dc.subject.meshHumans-
dc.subject.meshInterleukin-2-
dc.subject.meshMelanoma-
dc.subject.meshRecombinant Proteins-
dc.titleRecombinant interleukin-2 and other types of treatment of advanced malignant melanoma.en
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Oncology, Christie Hospital and Holt Radium Institute, Withington, Manchester, England.en
dc.identifier.journalCurrent Opinion in Oncologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.